- Home
- NAAS vs CODX Comparison
NAAS vs CODX Comparison
Compare NAAS & CODX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAAS
- CODX
- Stock Information
- Founded
- NAAS 2019
- CODX 2013
- Country
- NAAS China
- CODX United States
- Employees
- NAAS N/A
- CODX N/A
- Industry
- NAAS Other Specialty Stores
- CODX Medical/Dental Instruments
- Sector
- NAAS Consumer Discretionary
- CODX Health Care
- Exchange
- NAAS Nasdaq
- CODX Nasdaq
- Market Cap
- NAAS 8.3M
- CODX 9.8M
- IPO Year
- NAAS 2017
- CODX 2017
- Fundamental
- Price
- NAAS $2.75
- CODX $0.29
- Analyst Decision
- NAAS
- CODX Buy
- Analyst Count
- NAAS 0
- CODX 2
- Target Price
- NAAS N/A
- CODX $5.50
- AVG Volume (30 Days)
- NAAS 229.9K
- CODX 5.0M
- Earning Date
- NAAS 08-26-2025
- CODX 08-14-2025
- Dividend Yield
- NAAS N/A
- CODX N/A
- EPS Growth
- NAAS N/A
- CODX N/A
- EPS
- NAAS N/A
- CODX N/A
- Revenue
- NAAS $27,534,354.00
- CODX $1,003,653.00
- Revenue This Year
- NAAS $378.49
- CODX N/A
- Revenue Next Year
- NAAS N/A
- CODX $42.11
- P/E Ratio
- NAAS N/A
- CODX N/A
- Revenue Growth
- NAAS N/A
- CODX N/A
- 52 Week Low
- NAAS $1.96
- CODX $0.23
- 52 Week High
- NAAS $84.80
- CODX $2.23
- Technical
- Relative Strength Index (RSI)
- NAAS 48.66
- CODX 63.33
- Support Level
- NAAS $2.18
- CODX $0.24
- Resistance Level
- NAAS $2.90
- CODX $0.27
- Average True Range (ATR)
- NAAS 0.42
- CODX 0.02
- MACD
- NAAS 0.07
- CODX 0.00
- Stochastic Oscillator
- NAAS 57.48
- CODX 40.83
About NAAS NaaS Technology Inc.
Naas Technology Inc is an electric vehicle charging service provider in China, whose vision is to power the world with carbon-neutral energy. It offers an integrated set of online solutions to charging station operators. wide range of offline services that simplify the daily operations of charging station operators, and of non-charging services such as food and beverage services to station operators.
About CODX Co-Diagnostics Inc.
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.